UniProtKB/Swiss-Prot Q7L513: Variant p.Arg349Gln

Fc receptor-like A
Gene: FCRLA
Feedback?

Variant information Variant position:

349 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Arginine (R) to Glutamine (Q) at position 349 (R349Q, p.Arg349Gln). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from large size and basic (R) to medium size and polar (Q) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs11746 [ dbSNP | Ensembl ]

Sequence information Variant position:

349 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

359 The length of the canonical sequence.
Location on the sequence:

QDVRVLLGHLLMELRELSGH R KPGTTKATAE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         QDVRVLLGHLLMELRELSGHRKPGTTKATAE

Mouse                         QDVRALLGHLVMELRDLSVYLKPGTTKVADK

Rat                           QDVRILLGHLVMELRNLSAHRKPATTKS---

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	28 – 359	Fc receptor-like A

Literature citations
FCRL, a novel member of the leukocyte Fc receptor family possesses unique structural features.
Mechetina L.V.; Najakshin A.M.; Volkova O.Y.; Guselnikov S.V.; Faizulin R.Z.; Alabyev B.Y.; Chikaev N.A.; Vinogradova M.S.; Taranin A.V.;
Eur. J. Immunol. 32:87-96(2002)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 3; 4; 5; 6 AND 7); FUNCTION; SUBCELLULAR LOCATION; TISSUE SPECIFICITY; VARIANT GLN-349; An unusual Fc receptor-related protein expressed in human centroblasts.
Facchetti F.; Cella M.; Festa S.; Fremont D.H.; Colonna M.;
Proc. Natl. Acad. Sci. U.S.A. 99:3776-3781(2002)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 9); FUNCTION; SUBCELLULAR LOCATION; TISSUE SPECIFICITY; VARIANT GLN-349; Definition of an Fc receptor-related gene (FcRX) expressed in human and mouse B cells.
Davis R.S.; Li H.; Chen C.-C.; Wang Y.-H.; Cooper M.D.; Burrows P.D.;
Int. Immunol. 14:1075-1083(2002)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 9); TISSUE SPECIFICITY; VARIANT GLN-349; Submission
Guselnikov S.; Najakshin A.M.;
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2); VARIANT GLN-349; The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment.
Clark H.F.; Gurney A.L.; Abaya E.; Baker K.; Baldwin D.T.; Brush J.; Chen J.; Chow B.; Chui C.; Crowley C.; Currell B.; Deuel B.; Dowd P.; Eaton D.; Foster J.S.; Grimaldi C.; Gu Q.; Hass P.E.; Heldens S.; Huang A.; Kim H.S.; Klimowski L.; Jin Y.; Johnson S.; Lee J.; Lewis L.; Liao D.; Mark M.R.; Robbie E.; Sanchez C.; Schoenfeld J.; Seshagiri S.; Simmons L.; Singh J.; Smith V.; Stinson J.; Vagts A.; Vandlen R.L.; Watanabe C.; Wieand D.; Woods K.; Xie M.-H.; Yansura D.G.; Yi S.; Yu G.; Yuan J.; Zhang M.; Zhang Z.; Goddard A.D.; Wood W.I.; Godowski P.J.; Gray A.M.;
Genome Res. 13:2265-2270(2003)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 9); VARIANT GLN-349; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1); VARIANT GLN-349;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.